Project Grant P21AP11624

This $500,000 Cooperative Agreement award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) aims to establish the "Hybrid Operations to Promote Equity (HOPE)" initiative at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center. The project will address healthcare disparities in North Carolina's diverse patient population by engaging local providers in bi-directional educational efforts and developing user-friendly tools to...

This $104,096 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will support an integrated in silico and in vivo genetic screening approach to identify subtype-specific genetic dependencies in hepatocellular carcinoma (HCC). The University of Pittsburgh, the award recipient, will leverage deep learning models to predict HCC subtype-specific genetic dependencies and validate the findings using in vivo loss-of-function screening in preclinical HCC...

This $433,375 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients" (CFDA 93.376) program supports Adelphi University in delivering comprehensive support services for young breast cancer survivors and metastatic breast cancer patients. The five-year project, running from September 30, 2024 to September 29, 2029, focuses on increasing support for...

This Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will fund the establishment of the Human Prostate Tumor Atlas Center (HPTAC) at Washington University in St. Louis. The $1,032,520 award, effective September 1, 2024 through August 31, 2029, will support the development of a molecularly resolved spatial atlas of prostate cancer (PCa). The atlas will integrate multi-omics, imaging, and...

This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...

This Cooperative Agreement award of $460,000.00 from the Centers for Disease Control and Prevention (CDC), under the CFDA 93.376 "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients" program, aims to provide comprehensive support for young breast cancer survivors and metastatic breast cancer patients. The funding will be used by the Breast Cancer Resource Center, a non-profit organization, to increase support for caregivers and families,...

This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...

The U.S. Defense Health Agency awarded a $1,056,000.00 Project Grant to the Beckman Research Institute of the City of Hope, a nonprofit organization, to conduct research on PP2A as a promising biomarker and therapeutic target in small cell lung cancer. The grant period runs from September 1, 2023 to August 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The Beckman Research Institute, which has prior experience collaborating on federal health research...

The federal Cooperative Agreement award U54CA295336, titled "2/2 HOWARD - HOPKINS COMPREHENSIVE ALLIANCE IN CANCER RESEARCH, EDUCATION, AND EQUITY (H2CAREE)", is funded by the National Cancer Institute (CFDA 93.397 - Cancer Centers Support Grants) in the amount of $2,688,546.00. The award period runs from September 20, 2024 to August 31, 2029. The primary objectives of this award are to: 1) Establish and sustain collaborative cancer research programs with an emphasis on health...

This $1,149,870 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will establish a Pediatric Solid Tumor Microenvironment (PSTME) Atlas. The primary goal is to investigate the unique tumor microenvironments of prominent pediatric cancers like rhabdomyosarcoma, neuroblastoma, and Wilms tumors, with the aim of uncovering mechanisms of therapy resistance and identifying vulnerabilities for more...